This course includes differential diagnoses, pathogeneses, and treatment approaches and illustrates the role of the primary care provider and the oncologist in the management of metastic colorectal cancer. This online course guides the participant through clinical material in an engaging and interactive format.

NUMBER OF CREDIT HOURS: The Harvard Medical School designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This course should take approximately 1 hours to complete.

COST: $20.00 for the average learner. Participants living in emerging nations receive a 50% discount or can register for free. See our International Pricing Page for details.

OVERALL LEARNING OBJECTIVES:

1. Demonstrate several chemotherapeutic approaches to the treatment of metasatic colon cancer.
2. Examine the role of resection as well as targeted antibody agents in addressing metastatic colon cancer.

METHOD OF PARTICIPATION:

Registrants participate in the learning process by answering interactive multiple choice questions that are dispersed throughout the case presentation. You must answer a question correctly in order to continue through the course. If you answer a question incorrectly, you will be prompted to try again.

In order to earn credit, physicians must complete the entire educational activity before the termination date (see above). Non-physicians may register for the course but are not eligible for AMA PRA Category 1 Credits™. Instead, non-physicians will earn a certificate of participation after successfully completing the course before its termination date.

COMBINATION OF MEDIA USED:

This internet enduring material is a case-based, interactive presentation comprised mainly of text, interactive questions, and images. A variety of media, including video clips, audio clips, and Flash animation, may be presented. Links to any necessary plugins are provided when necessary, but no plugins are required for general use of the CME website, and you may skip the multimedia presentation(s) within the course if you choose.

back to the top

JEFFREY MEYERHARDT, MD, MPH Course Director

Dr. Meyerhardt is an Associate Physician of the Department of Medical Oncology at the Dana-Farber Cancer Institute, member of the Gastrointestinal Cancer Center and Assistant Professor of Medicine at Harvard Medical School. Dr. Meyerhardt conducts outcomes research in patients with gastrointestinal cancer, particularly the relationship between diet and lifestyle on patients with colorectal cancer. In addition, he has served as lead investigator and co-investigator of multiple clinical trials for patients with gastrointestinal cancers. Dr. Meyerhardt received his undergraduate degree from Haverford College, medical degree at Yale School of Medicine and Masters of Public Health at the Harvard School of Public Health. DISCLOSURE: Consultant: Sanofi, taught module on basics of colorectal cancer to sales staff Consultant: Bayer, early phase development of oncology drug Prior to 2011: Consultant for Amgen (< 10 K). Research funding (to institution): Bristol-Myers Squibb and Astra Zeneca Prior to 2010: Sanofi-aventis: Consultant (<10 K/year): Treatment, Pfizer Inc., Genetech, Bristol Myer Squibb

back to the top

STEPHEN A. CANNISTRA, MD Reviewer

Dr. Cannistra is the Director of Gynecologic Medical Oncology and is an accomplished scholar in gynecologic malignancies, with a national and international reputation in the field of ovarian cancer. His group’s research efforts focus on the development of novel approaches to the treatment of newly diagnosed and relapsed ovarian cancer. Several investigator-initiated trials have already been developed in his program, including the use of an oral VEGF-R inhibitor for treatment of marker-only relapse, as well as consolidation approaches using oral topotecan in patients who have achieved complete clinical remission. Current clinical trials are designed to target the angiogenic pathway, using bevacizumab in combination with first-line chemotherapy, or as a single agent in relapsed disease. More recently, his group was the first to identify a microarray gene expression profile, referred to as the OCPP, that has powerful and independent prognostic value in ovarian cancer. His group's ongoing work in this area has revealed other gene expression patterns which are predictive of response to chemotherapy, as defined by the results of second-look laparoscopies. This work is made possible through the use of a large ovarian cancer tissue bank and correlative clinical database that Dr. Cannistra has developed over the past decade. Dr. Cannistra is a co-Principal Investigator on the DF/HCC Ovarian Cancer SPORE, serves as an Associate Editor and Medical Science Consulting Editor for the Journal of Clinical Oncology, and has served as program chair for the Gynecologic Cancer Committee of the American Society of Clinical Oncology (ASCO). He also serves on the Program Committee of the Society of Gynecologic Oncologists and is media spokesperson for ASCO in the fields of tumor biology and gynecologic malignancies. DISCLOSURE: Reported no relevant financial relationships with commercial entities.

MARK S. HUBERMAN, MD Reviewer

Dr. Huberman is an Assistant Professor of Medicine at Beth Israel Deaconess Medical Center in Boston, MA. DISCLOSURE: Reported no relevant financial relationships with commercial entities.

back to the top

SANJIV CHOPRA, MD Planner

Dr. Sanjiv Chopra is Professor of Medicine and Faculty Dean for Continuing Medical Education at Harvard Medical School and Senior Consultant in Hepatology at the Beth Israel Deaconess Medical Center, Boston. In his role as Faculty Dean for Continuing Education, Dr. Chopra provides oversight and leadership of the Department and oversees the academic development of our programs. Dr. Chopra is an experienced clinician, researcher, and educator. In his research roles, he has served both as a principal investigator as well as co-investigator. He has more than 120 publications and five books to his credit, addressing topics in disease states, patient care, and leadership. Dr. Chopra’s teaching experience is extensive, and he has won numerous teaching awards for his work with medical students, residents and physicians. Currently, he directs and speaks at 10 multiday CME courses, nine of which are through HMS. For his full bio, please click here. DISCLOSURE: Reported no relevant financial relationships with commercial entities.

ANDI LONG, EDM Planner

Andi Long directs the Department of Continuing Education’s Distance Learning group, which offers a variety of online continuing medical education programs to health care professionals around the world. Andi develops strategies for new pilot programs and systematically rolls out new distance learning initiatives and has a leadership role in IT planning and other online processes for HMS DCE. She oversees the day-to-day operations of each distance learning activity and ensures ACCME compliance across all enduring programs. She has had the privilege of working with hundreds of Harvard Medical School Faculty members to develop high-quality, engaging online programs that physicians in more than 170 countries have taken part in. Andi earned her Ed.M. in Technology, Innovation, and Education from Harvard Graduate School of Education and graduated from Bridgewater State College, summa cum laude, with a degree in English. Her professional interests focus on teaching and learning with new technologies and online course development. DISCLOSURE: Reported no relevant financial relationships with commercial entities.

back to the top

NUMBER OF CREDITS: 1 

The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Harvard Medical School designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This course should take approximately 1 hours to complete.

Within 2 weeks of completing the course, you will receive your certificate via email.

Click the image to view a sample of the certificate

back to the top